Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CPHI

CPHI - China Pharma Holdings Inc Stock Price, Fair Value and News

$1.27-0.03 (-2.31%)
Market Closed

43/100

CPHI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

43/100

CPHI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.21

Target 3M

$1.23

Target 6M

$1.23

CPHI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CPHI Price Action

Last 7 days

3.3%

Last 30 days

2.4%

Last 90 days

-26.6%

Trailing 12 Months

-44.8%

CPHI RSI Chart

CPHI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CPHI Valuation

Market Cap

6.4M

Price/Earnings (Trailing)

-2

Price/Sales (Trailing)

1.57

EV/EBITDA

-3.65

Price/Free Cashflow

40.8

CPHI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.21

Target 3M

$1.23

Target 6M

$1.23

CPHI Fundamentals

CPHI Revenue

Revenue (TTM)

4.1M

Rev. Growth (Yr)

-31.26%

Rev. Growth (Qtr)

-26.28%

CPHI Earnings

Earnings (TTM)

-3.2M

Earnings Growth (Yr)

41.72%

Earnings Growth (Qtr)

-23.3%

CPHI Profitability

Operating Margin

-10.94%

EBT Margin

-78.72%

Return on Equity

-38.37%

Return on Assets

-20.18%

Free Cashflow Yield

2.45%

CPHI Investor Care

Shares Dilution (1Y)

160.84%

Diluted EPS (TTM)

-1.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20254.3M4.4M4.1M0
20246.4M6.2M5.5M4.5M
20238.5M7.9M7.8M7.0M
20228.9M8.1M8.1M8.1M
202111.5M10.1M9.7M9.6M
20209.8M11.0M11.0M10.9M
201911.6M11.0M11.1M10.9M
201813.5M13.8M12.9M12.3M
201715.4M14.7M13.9M13.2M
201618.3M17.6M16.8M16.1M
201520.7M20.3M19.2M20.4M
201431.7M29.8M27.2M22.1M
201346.7M40.1M36.0M32.8M
201279.1M74.1M65.3M54.5M
201176.1M77.8M79.5M81.2M
201000074.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About China Pharma Holdings Inc

CPHI
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. The company also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. It offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. The company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.
 CEO
 WEBSITEchinapharmaholdings.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES234

China Pharma Holdings Inc Frequently Asked Questions

CPHI is the stock ticker symbol of China Pharma Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of China Pharma Holdings Inc is 6.38 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check CPHI's fair value in chart for subscribers.

The fair value guage provides a quick view whether CPHI is over valued or under valued. Whether China Pharma Holdings Inc is cheap or expensive depends on the assumptions which impact China Pharma Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CPHI.

As of Wed Jan 28 2026, CPHI's PE ratio (Price to Earnings) is -2 and Price to Sales (PS) ratio is 1.57. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CPHI PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, China Pharma Holdings Inc has provided -0.33 (multiply by 100 for percentage) rate of return.